Opus Genetics (IRD) – Analysts’ Recent Ratings Changes

Opus Genetics (NASDAQ: IRD) has recently received a number of price target changes and ratings updates:

• 11/11/2026 – Opus Genetics had its price target raised by Royal Bank Of Canada from $9.00 to $11.00. They now have an “outperform” rating on the stock.
• 11/11/2026 – Opus Genetics had its price target raised by HC Wainwright from $8.00 to $14.00. They now have a “buy” rating on the stock.
• 11/7/2026 – Opus Genetics was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/22/2026 – Opus Genetics had its “buy” rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.
• 10/16/2026 – Opus Genetics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $17.00 price target on the stock.
• 10/15/2026 – Opus Genetics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/6/2026 – Opus Genetics had its price target raised by JonesTrading from $10.00 to $17.00. They now have a “buy” rating on the stock.
• 10/4/2026 – Opus Genetics was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/2/2026 – Opus Genetics had its “buy” rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.
• 9/26/2026 – Opus Genetics was downgraded by Wall Street Zen from “hold” to “sell”.

Opus Genetics Stock Down 5.8%

Opus Genetics stock traded down $0.25 during midday trading on Thursday, hitting $4.06. 1,387,998 shares of the stock were exchanged, compared to its average volume of 1,411,308. The stock has a market capitalization of $335.56 million, a PE ratio of -2.60 and a beta of 0.80. The company has a fifty day simple moving average of $4.50 and a two-hundred day simple moving average of $4.23. Opus Genetics, Inc. has a 52 week low of $1.70 and a 52 week high of $7.07.

Opus Genetics (NASDAQ:IRD) last issued its earnings results on Tuesday, November 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.31). The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $1.55 million. As a group, equities research analysts anticipate that Opus Genetics, Inc. will post -0.97 EPS for the current fiscal year.

Insider Activity

In other Opus Genetics news, President Benjamin R. Yerxa sold 33,189 shares of Opus Genetics stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $3.54, for a total transaction of $117,489.06. Following the transaction, the president directly owned 670,917 shares in the company, valued at approximately $2,375,046.18. The trade was a 4.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 556,000 shares of the business’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $4.96, for a total value of $2,757,760.00. Following the completion of the transaction, the director directly owned 3,236,171 shares of the company’s stock, valued at approximately $16,051,408.16. The trade was a 14.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 673,805 shares of company stock worth $3,213,582 over the last quarter. Corporate insiders own 11.70% of the company’s stock.

Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, rare conditions that can cause progressive vision loss. Its programs target specific genetic causes of these disorders, including mutations associated with Leber congenital amaurosis and retinitis pigmentosa. The company’s therapies are investigational and are designed to address the underlying genetic defects rather than only manage symptoms. Opus Genetics was formed through the combination of Opus Genetics and Ocuphire Pharma; the combined company took the Opus Genetics name and began trading on Nasdaq under the symbol IRD in 2024.